ReviewClinical reviews in allergy & immunology2018
Unmet Needs in Axial Spondyloarthritis.
Review in Clinical reviews in allergy & immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- The journey of Europeans with musculoskeletal complaints: the creation of the SPIDeRR's personas.EULAR rheumatology open · 2026Article
- The patient journey in rheumatic and musculoskeletal diseases: a systematic review.EULAR rheumatology open · 2025Article
- The journey of patients with musculoskeletal complaints in Europe: a cross-sectional European survey.Rheumatology international · 2025Article
- Elevating the Standard of Care for Patients with Axial Spondyloarthritis: 'Calls to Action' from Rheumacensus, a Multistakeholder Pan-European Initiative.Rheumatology and therapy · 2024Article
- A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.Rheumatology (Oxford, England) · 2022Review
- Early identification of axial spondyloarthritis in a multi-ethnic Asian population.Clinical rheumatology · 2022Article
- Therapeutic Targets for Ankylosing Spondylitis - Recent Insights and Future Prospects.Open access rheumatology : research and reviews · 2022Review
- Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study.BMC family practice · 2021Article
- Review
- Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study.BMC family practice · 2020Article
- Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study.Rheumatology and therapy · 2020Article
- MicroRNAs in ankylosing spondylitis: Function, potential and challenges.Journal of translational autoimmunity · 2020Review
- New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review.Rheumatology and therapy · 2019Review
- Application of machine learning in the diagnosis of axial spondyloarthritis.Current opinion in rheumatology · 2019Review
- Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.Rheumatology international · 2019Observational
- Role of comorbidities in spondyloarthritis including psoriatic arthritis.Clinical rheumatology · 2019Review
- Autoimmunity in 2017.Clinical reviews in allergy & immunology · 2018Review
- The long and latent road to autoimmunity.Cellular & molecular immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the past decade, the well-known disease called ankylosing spondylitis has come to be considered as a subset of the broader entity referred as axial spondyloarthritis (axSpA), which also includes non-radiographic axSpA. The need of this new classification was aimed to improve the sensitivity for an early diagnosis, to reduce diagnostic delay, and to allow an early treatment. Although there is improvement in the recognition, the management of patients, and the treatment strategies of axSpA, unmet needs persist. There is still a substantial gap of 5-8 years between the onset of symptoms and the diagnosis of axSpA and, even in patients diagnosed early, 20-40% of them do not respond or have a loss of response to anti-TNF treatment. Moreover, the pathogenesis of the disease and, in particular, the mechanisms of new bone formation are far to be completely understood. Nevertheless, the discovery of IL-23/IL-17 axis with the development of biologic inhibitors, the identification of new subsets of effector cells, together with the interest in the detection of potential biomarkers of bone formation brought the approach to axSpA into a new era. This review is intended to enhance awareness and understanding of axSpA and to identify and discuss the current unmet needs in axSpA, including diagnosis, classification, biomarkers, pathogenesis, management, and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.